Brazil puts over US$1bn into H1N1 care
This article was originally published in Clinica
Executive Summary
Diagnostic supplies, hospital equipment and additional intensive care capacity are among the beneficiaries of a R$2.18bn (US$1.16bn) emergency fund approved by the Brazilian government to help tackle H1N1 "swine" flu. The funds (which will also be used to acquire 73 million vaccine doses and over 11 million courses of antivirals) will be disbursed rapidly, said federal health minister José Gomes Temporão on August 27. The main aim of this "provisional measure" is to prepare for an expected worsening of what will "certainly be a rapidly changing situation [globally]", he said. Brazil ranks seventh in the world among countries with the highest official H1N1 mortality, which are mainly in the southern hemisphere, where the winter flu season is peaking.
You may also be interested in...
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.